Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

被引：84

作者：

Shepherd, FA ^{[1
]}

Tsao, MS

机构：

[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[2] Univ Toronto, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 07期

关键词：

D O I：

10.1200/JCO.2005.04.4420

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1219 / 1220

页数：2

共 8 条

[1] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[2]

Gumerlock PH, 2005, J CLIN ONCOL, V23, p623S

[3] Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study [J].

Hirsch, FR ;

Varella-Garcia, M ;

McCoy, J ;

West, H ;

Xavier, AC ;

Gumerlock, P ;

Bunn, PA ;

Franklin, WA ;

Crowley, J ;

Gandara, DR .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6838-6845

[4] Selecting patients for epidermal growth factor receptor inhibitor treatment:: A FISH story or a tale of mutations? [J].

Johnson, BE ;

Jänne, PAJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6813-6816

[5] EGFR and ErbB2 mutation status in Japanese lung cancer patients [J].

Sasaki, H ;

Shimizu, S ;

Endo, K ;

Takada, M ;

Kawahara, M ;

Tanaka, H ;

Matsumura, A ;

Iuchi, K ;

Haneda, H ;

Suzuki, E ;

Kobayashi, Y ;

Yano, M ;

Fujii, Y .

INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (01) :180-184

[6] Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

[7] Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer [J].

Takano, T ;

Ohe, Y ;

Sakamoto, H ;

Tsuta, K ;

Matsuno, Y ;

Tateishi, U ;

Yamamoto, S ;

Nokihara, H ;

Yamamoto, N ;

Sekine, I ;

Kunitoh, H ;

Shibata, T ;

Sakiyama, T ;

Yoshida, T ;

Tamura, T .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6829-6837

[8] Erlotinib in lung cancer - Molecular and clinical predictors of outcome [J].

Tsao, MS ;

Sakurada, A ;

Cutz, JC ;

Zhu, CQ ;

Kamel-Reid, S ;

Squire, J ;

Lorimer, I ;

Zhang, T ;

Liu, N ;

Daneshmand, M ;

Marrano, P ;

Santos, GD ;

Lagarde, A ;

Richardson, F ;

Seymour, L ;

Whitehead, M ;

Ding, KY ;

Pater, J ;

Shepherd, FA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :133-144

← 1 →